文献速递泌尿生殖腹部技术与安全CTPET

自动化容积iRECIST评估mRCC免疫治疗反应的可行性

Automated volumetric iRECIST-inspired CT assessment of treatment response to dual immune checkpoint inhibition in metastatic renal cell carcinoma: A feasibility study.
PubMed 文献 · Eur J Radiol · 2026-07-08

本研究回顾性收集75例接受伊匹木单抗/纳武利尤单抗治疗的转移性肾细胞癌患者,利用全身病灶自动分割与纵向追踪生成容积iRECIST评分。结果显示该自动化方法具有可行性,并可显著提高观察者间一致性。

要点

  • 自动化容积iRECIST评分在mRCC中可行,可用于辅助疗效评估
  • AI辅助后观察者间一致性从κ=0.34提升至κ=0.67
  • 病灶追踪准确性高(0.98),新病灶检测准确性0.85

核心结论

  • 自动化容积iRECIST-inspired评分在mRCC患者中具有可行性,并能改善观察者间一致性
  • 该方法支持基于iRECIST的可解释性疗效评估

研究设计与样本

  • 回顾性单中心研究,纳入2019-2024年75例接受伊匹木单抗/纳武利尤单抗的mRCC患者
  • 收集治疗前及间隔12周的CECT或PET/CT随访扫描,由3名放射科医生独立评分并借助自动化输出复评15例测试病例

关键影像表现/征象

  • 自动化全身病灶分割在基线和随访中Dice评分分别为0.74和0.60
  • 基线每扫描假阳性中位数2.4个,随访假阳性中位数0.6个
  • 病灶追踪准确性0.98,F1评分0.90,新病灶检测准确性0.85

诊断标准与关键数值

  • 与共识的一致性:第一次随访κ=0.60(95% CI 0.50-0.68),第二次随访κ=0.44(95% CI 0.31-0.54)
  • AI辅助使观察者间一致性从κ=0.34(95% CI 0.11-0.56)提升至κ=0.67(95% CI 0.40-0.89,p=0.04)

临床应用与阅片要点

  • 自动化容积iRECIST评分可作为mRCC免疫治疗疗效评估的辅助工具
  • 自动病灶追踪和新病灶检测可帮助放射科医生减少观察者间变异
  • 临床应用时需注意随访中分割Dice评分低于基线,可能影响小病灶评估

局限性

  • 单中心回顾性研究设计
  • 随访分割Dice评分较低(0.60),可能限制小病灶或复杂病灶的准确评估

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Evaluate the feasibility and interobserver variability of automated volumetric immune Response Evaluation Criteria in Solid Tumours (iRECIST)-inspired scoring of treatment response in metastatic renal cell carcinoma (mRCC).

MATERIALS AND METHODS: Pretreatment and follow-up CECT or PET/CT scans at 12-week intervals were retrospectively collected from 75 mRCC patients receiving ipilimumab/nivolumab at a single centre (2019-2024). Whole-body lesion segmentation and longitudinal tracking were used to derive volumetric iRECIST-inspired scores. Three radiologists independently assigned iRECIST scores, then re-evaluated 15 test patients using the automated output. Performance was assessed using Dice score, false positives, tracking accuracy, F1, and new lesion detection accuracy (NLDA). Interobserver agreement was compared before and after AI assistance using multi-level κ statistics (p < 0.05).

RESULTS: Seventy-five patients (65.6 ± 9.8 years, 74.7 % male) were included. Dice scores post-revision were 0.74 (IQR: 0.71-0.78) and 0.60 (IQR: 0.56-0.64) at baseline and follow-up, with 2.4 (IQR: 2.1-2.7) and 0.6 (IQR: 0.5-0.8) false positives per scan, respectively. Tracking accuracy was 0.98 (IQR: 0.98-1.00), F1 score 0.90 (IQR: 0.80-1.00), and NLDA 0.85 (IQR: 0.80-1.00). Agreement with the consensus yielded κ = 0.60 (95 % CI: 0.50-0.68) and κ = 0.44 (95 % CI: 0.31-0.54) at first and second follow-up. AI assistance significantly improved interobserver agreement from κ = 0.34 (95 % CI 0.11-0.56) to κ = 0.67 (95 % CI 0.40-0.89; p = 0.04).

CONCLUSION: Automated volumetric iRECIST-inspired scoring in mRCC patients is feasible and improves interobserver agreement, supporting an interpretable iRECIST-based response assessment.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Kraaijveld, Ma, Suelmann, et al. Automated volumetric iRECIST-inspired CT assessment of treatment response to dual immune checkpoint inhibition in metastatic renal cell carcinoma: A feasibility study. Eur J Radiol. 2026. PMID: 42468161. doi:10.1016/j.ejrad.2026.113057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。